LPL Financial
MLTX icon

LPL Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

LPL Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,338
Closed -$299K – 5917
2025
Q2 		$299K Sell
6,338
-2,509
-28% -$102K ﹤0.01% 4780
2025
Q1 		$346K Buy
8,847
+701
+9% +$30.2K ﹤0.01% 4477
2024
Q4 		$441K Buy
8,146
+1,332
+20% +$68K ﹤0.01% 4208
2024
Q3 		$344K Buy
6,814
+319
+5% +$14.9K ﹤0.01% 4317
2024
Q2 		$286K Sell
6,495
-151
-2% -$6.4K ﹤0.01% 4308
2024
Q1 		$334K Sell
6,646
-620
-9% -$33.6K ﹤0.01% 4118
2023
Q4 		$439K Buy
7,266
+404
+6% +$20.8K ﹤0.01% 3769
2023
Q3 		$391K Buy
6,862
+767
+13% +$42.3K ﹤0.01% 3683
2023
Q2 		$311K Buy
+6,095
New +$164K ﹤0.01% 3818

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

LPL Financial's MLTX Position: Q3 2025 in Review

LPL Financial sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 6,338 shares — an estimated $299K sold.

LPL Financial first reported a position in MLTX in Q2 2023 and held it in 9 quarters. The position peaked at $441K in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • LPL Financial reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • LPL Financial sold 6,338 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $299K.
  • LPL Financial first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 9 quarters.
  • LPL Financial's MoonLake Immunotherapeutics position peaked at $441K in Q4 2024.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on LPL Financial's 13F filing for Q3 2025, filed 12 Nov 2025.